Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study of PRO-203 in Healthy Adult Volunteers Followed by an Open-label, Single-ascending-dose With Priming Study of PRO-203 in Participants With Systemic Sclerosis

NCT07641634 is registered in ClinicalTrials.gov with Prolium Bioscience, Inc as lead sponsor.

NCT NCT07641634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07641634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study of PRO-203 in Healthy Adult Volunteers Followed by an Open-label, Single-ascending-dose With Priming Study of PRO-203 in Participants With Systemic Sclerosis
Lead sponsor
Prolium Bioscience, Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 27, 2025
Completion date
January 31, 2028
Enrollment
44 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, scleroderma, scleroderma, systemic, systemic sclerosis (ssc)